Mylan (MYL) has introduced a generic version of its EpiPens after public outrage over its pricing. But TheStreet's Jim Cramer says he's happy the company rolled back prices, but he still isn't a fan of the stock.
More from Video
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.
AMSC CEO discusses that and China challenges.
One of pharma's biggest CEO's talks M&A action on the exchange.